Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q4 FY21 results · Jan–Mar 2021
Torrent Pharmaceuticals reported revenue from operations of ₹1,937.00 crore (down 0.5% from Q4 FY20) and net profit of ₹324.00 crore (up 3.2% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,937.00 | 1,946.00 | −0.5% | 1,995.00 | −2.9% |
| Other income | 39.00 | 15.00 | +160.0% | 8.00 | +387.5% |
| Total income | 1,976.00 | 1,961.00 | +0.8% | 2,003.00 | −1.3% |
| Profit before tax | 383.00 | 293.00 | +30.7% | 357.00 | +7.3% |
| Net profit for the period | 324.00 | 314.00 | +3.2% | 297.00 | +9.1% |
| EPS, basic (₹) | 19.16 | 18.56 | +3.2% | 17.52 | +9.4% |
| Net margin (%) | 16.7 | 16.1 | 14.9 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,468.00 | 1,491.00 | −1.5% | 1,616.00 | −9.2% |
| Other income | 91.00 | 21.00 | +333.3% | 11.00 | +727.3% |
| Total income | 1,559.00 | 1,512.00 | +3.1% | 1,627.00 | −4.2% |
| Profit before tax | 301.00 | 195.00 | +54.4% | 339.00 | −11.2% |
| Net profit for the period | 279.00 | 168.00 | +66.1% | 278.00 | +0.4% |
| EPS, basic (₹) | 16.48 | 9.91 | +66.3% | 16.45 | +0.2% |
| Net margin (%) | 19.0 | 11.3 | 17.2 |
Consolidated
- Filed with BSE
- 18 May 2021, 18:35 IST
- Board meeting
- 18 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 May 2021, 18:35 IST
- Board meeting
- 18 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE